The short version
Only one company currently supplies this market — there is no backup if it stumbles.
Market view
palbociclib · Capsule
3 marketed package NDCs · 1 active manufacturer
What changed in the last 90 days
Every detected change for palbociclib, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.
- PalbociclibAug 12, 2026Mfr exitedShanghai Huilun Jiangsu Pharmaceutical Co., Ltd. · palbociclib
Same drug class
Other molecules FDA puts in Kinase Inhibitor, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
Common questions
- Is Palbociclib in shortage right now?
- No. FDA does not currently list Palbociclib in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Palbociclib?
- 17 companies have marketed Palbociclib in the last 30 days, according to the FDA NDC Directory. Every manufacturer and package is listed on this page.
Shortage reports for this molecule
- Planned discontinuation — Ibrance, Capsule, 100 mg (NDC 0069-0188-21)Apr 22, 2026
- Planned discontinuation — Ibrance, Capsule, 75 mg (NDC 0069-0187-21)Apr 22, 2026
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.